nach oben

Indian Journal of Otolaryngology and Head & Neck Surgery

Erschienen in:

07.10.2021 | Original Article

The Association Between Vitamin D Level and PFAPA Syndrome: A Systematic Review

verfasst von: Sara A. Faydhi, Hala M. A. Kanawi, Talal Al-Khatib, Faisal Zawawi

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Sonderheft 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Periodic Fever, Aphthous Ulcers, Pharyngitis and Adenitis (PFAPA) Syndrome’s etiology is not well understood. The objective of this study is to explore the association between vitamin D level and PFAPA syndrome. A systematic review of all publications addressing the association between vitamin D level and PFAPA syndrome prior to May 2019 was conducted. Data were collected from online medical databases namely, PubMed, Ovid Medline, Embase, Cochrane Library, Google Scholar, and Scopus. The review adhered to the PRISMA statement and was performed in 3 main phases; an initial screening review of abstracts was performed, followed by a detailed review of full articles based on inclusion and exclusion criteria, and lastly a final review to extract data from selected articles. 3 prospective review-based and one case report articles were included with a total of 281 patients, 98 of whom were cases of PFAPA, while 183 were controls. Vitamin D levels were deficient in 27% of PFAPA group as compared with the control. Vitamin D supplementation was given as an initial treatment in 25/98 of the patients. Only 1 patient received it as a second treatment. After vitamin D supplementation, a marked reduction of the number of febrile episodes and modification of the mean duration were recognized. There may be an association between Vitamin D deficiency and a higher frequency of PFAPA episodes. Vitamin D supplementation in children with PFAPA may reduce the frequency of episodes and help manage the condition.

Nalbantoğlu A, Nalbantoğlu B (2019) Vitamin D deficiency as a risk factor for PFAPA syndrome. Int J Pediatr Otorhinolaryngol 121(September 2018):55–57. https://doi.org/10.1016/j.ijporl.2019.02.047CrossRef

Mahamid M, Agbaria K, Mahamid A, Nseir W (2013) Vitamin D linked to PFAPA syndrome. Int J Pediatr Otorhinolaryngol 77(3):362–364. https://doi.org/10.1016/j.ijporl.2012.11.027CrossRef

Thomas KT, Feder HMJ, Lawton AR, Edwards KM (1999) Periodic fever syndrome in children. J Pediatr 135(1):15–21. https://doi.org/10.1016/s0022-3476(99)70321-5CrossRef

Padeh S, Brezniak N, Zemer D et al (1999) Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome. J Pediatr 135(1):98–101. https://doi.org/10.1016/s0022-3476(99)70335-5CrossRef

Tasher D, Somekh E, Dalal I (2006) PFAPA syndrome: new clinical aspects disclosed. Arch Dis Child 91(12):981–984. https://doi.org/10.1136/adc.2005.084731CrossRef

Feder HM, Salazar JC (2010) A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr 99(2):178–184. https://doi.org/10.1111/j.1651-2227.2009.01554.xCrossRef

Stojanov S, Lapidus S, Chitkara P et al (2011) Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A 108(17):7148–7153. https://doi.org/10.1073/pnas.1103681108CrossRef

Gaggiano C, Rigante D, Sota J, Grosso S, Cantarini L (2019) Treatment options for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome in children and adults: a narrative review. Clin Rheumatol 38(1):11–17. https://doi.org/10.1007/s10067-018-4361-2CrossRef

Penna G, Amuchastegui S, Giarratana N et al (2007) 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178(1):145–153. https://doi.org/10.4049/jimmunol.178.1.145CrossRef

10.

Penna G, Adorini L (2000) 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164(5):2405–2411. https://doi.org/10.4049/jimmunol.164.5.2405CrossRef

11.

Antico A, Tampoia M, Tozzoli R, Bizzaro N (2012) Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 12(2):127–136. https://doi.org/10.1016/j.autrev.2012.07.007CrossRef

12.

Stagi S, Bertini F, Rigante D, Falcini F (2014) Vitamin D levels and effects of vitamin D replacement in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. Int J Pediatr Otorhinolaryngol 78(6):964–968. https://doi.org/10.1016/j.ijporl.2014.03.026CrossRef

13.

Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52(6):377–384. https://doi.org/10.1136/jech.52.6.377CrossRef

14.

Rico Rodes A, SabridoBermúdez G, Llombart Vidal A, AlcaláMinagorre PJ (2016) Periodic fever, aphthous stomatitis, pharyngitis and adenopathy syndrome and vitamin D: a possible treatment option? Reumatol Clínica (Engl Ed.) 12(6):363–364. https://doi.org/10.1016/j.reumae.2015.11.015CrossRef

15.

Lemire JM, Archer DC, Reddy GS (1994) 1,25-Dihydroxy-24-OXO-16ene-vitamin D3, a renal metabolite of the vitamin D analog 1,25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 135(6):2818–2821. https://doi.org/10.1210/endo.135.6.7988477CrossRef

16.

Cantorna MT, Woodward WD, Hayes CE, DeLuca HF (1998) 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 160(11):5314–5319CrossRef

17.

Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R (1994) Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 37(6):552–558. https://doi.org/10.1007/BF00403372CrossRef

18.

Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R (1995) Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 136(3):866–872. https://doi.org/10.1210/endo.136.3.7867594CrossRef

19.

Casteels KM, Mathieu C, Waer M et al (1998) Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A. Endocrinology 139(1):95–102. https://doi.org/10.1210/endo.139.1.5641CrossRef

20.

Cantorna MT, Hayes CE, DeLuca HF (1998) 1,25-dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 128(1):68–72. https://doi.org/10.1093/jn/128.1.68CrossRef

21.

Tetlow LC, Woolley DE (1999) The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res 1(1):63–70. https://doi.org/10.1186/ar12CrossRef

22.

Lips P (2004) Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 89–90(1–5):611–614. https://doi.org/10.1016/j.jsbmb.2004.03.040CrossRef

23.

Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS (2006) Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 5(2):114–117. https://doi.org/10.1016/j.autrev.2005.05.009CrossRef

24.

Onur H, Aral H, Arica V, Bercem GA, Kasapcopur O (2016) Vitamin D levels in children with familial Mediterranean fever. Pediatr Rheumatol 14(1):1–5. https://doi.org/10.1186/s12969-016-0089-1CrossRef

25.

Cutolo M, Pizzorni C, Sulli A (2011) Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 11(2):84–87. https://doi.org/10.1016/j.autrev.2011.08.003CrossRef

26.

Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66(9):1137–1142. https://doi.org/10.1136/ard.2007.069831CrossRef

27.

Peelen E, Knippenberg S, Muris A-H et al (2011) Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 10(12):733–743. https://doi.org/10.1016/j.autrev.2011.05.002CrossRef

28.

Rigante D, Vitale A, Natale MF et al (2017) A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. Clin Rheumatol 36(2):463–468. https://doi.org/10.1007/s10067-016-3317-7CrossRef

29.

Carvalho JF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y (2007) Anti-vitamin D, vitamin D in SLE: preliminary results. Ann N Y Acad Sci 1109:550–557. https://doi.org/10.1196/annals.1398.061CrossRef

30.

Lin TC, Wu JY, Kuo ML, Ou LS, Yeh KW, Huang JL (2018) Correlation between disease activity of pediatric-onset systemic lupus erythematosus and level of vitamin D in Taiwan: a case–cohort study. J Microbiol Immunol Infect 51(1):110–114. https://doi.org/10.1016/j.jmii.2015.12.005CrossRef

31.

Moghimi J, Sadeghi A, Malek M, Ghorbani R (2012) Relationship between disease activity and serum levels of vitamin D and parathyroid hormone in rheumatoid arthritis. Endocr Regul 46(2):61–66. https://doi.org/10.4149/endo_2012_02_61CrossRef

32.

Kamen D, Aranow C (2008) Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol 20(5):532–537. https://doi.org/10.1097/BOR.0b013e32830a991bCrossRef

33.

Mirza AA, Alharbi AA, Marzouki H, Al-Khatib T, Zawawi F (2020) The association between vitamin D deficiency and recurrent tonsillitis: a systematic review and meta-analysis. Otolaryngol-Head Neck Surg (U S). https://doi.org/10.1177/0194599820935442CrossRef

34.

Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H (2012) Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Patti F, ed. Mult Scler Int 2012:452541. https://doi.org/10.1155/2012/452541CrossRef

35.

Goldberg P, Fleming MC, Picard EH (1986) Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 21(2):193–200. https://doi.org/10.1016/0306-9877(86)90010-1CrossRef

36.

Andjelkovic Z, Vojinovic J, Pejnovic N et al (1999) Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 17(4):453–456

37.

Brohult J, Jonson B (1973) Effects of large doses of calciferol on patients with rheumatoid arthritis. A double-blind clinical trial. Scand J Rheumatol 2(4):173–176. https://doi.org/10.3109/03009747309097085CrossRef

38.

Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide M-V, Aguirre C (2010) Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. Arthritis Care Res (Hoboken) 62(8):1160–1165. https://doi.org/10.1002/acr.20186CrossRef

39.

Caca-Biljanovska NG, Vlckova-Laskoska MT, Dervendi DV, Pesic NP, Laskoski DS (1999) Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 455:299–304. https://doi.org/10.1007/978-1-4615-4857-7_44CrossRef

40.

Elst EF, Van Suijlekom-Smit LW, Oranje AP (1999) Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 16(1):53–58. https://doi.org/10.1046/j.1525-1470.1999.99016.xCrossRef

41.

Hulshof MM, BouwesBavinck JN, Bergman W et al (2000) Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 43(6):1017–1023. https://doi.org/10.1067/mjd.2000.108369CrossRef

42.

Humbert P, Dupond JL, Agache P et al (1993) Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol 73(6):449–451. https://doi.org/10.2340/0001555573449451CrossRef

43.

Hiremath GS, Cettomai D, Baynes M et al (2009) Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 15(6):735–740. https://doi.org/10.1177/1352458509102844CrossRef

44.

Wingerchuk DM, Lesaux J, Rice GPA, Kremenchutzky M, Ebers GC (2005) A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76(9):1294–1296. https://doi.org/10.1136/jnnp.2004.056499CrossRef

45.

Burton JM, Kimball S, Vieth R et al (2010) A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 74(23):1852–1859. https://doi.org/10.1212/WNL.0b013e3181e1cec2CrossRef

46.

Li X, Liao L, Yan X et al (2009) Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 25(5):411–416. https://doi.org/10.1002/dmrr.977CrossRef

47.

Pitocco D, Crinò A, Di Stasio E et al (2006) The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset type 1 diabetes (IMDIAB XI). Diabet Med 23(8):920–923. https://doi.org/10.1111/j.1464-5491.2006.01921.xCrossRef

Titel: The Association Between Vitamin D Level and PFAPA Syndrome: A Systematic Review
verfasst von: Sara A. Faydhi
Hala M. A. Kanawi
Talal Al-Khatib
Faisal Zawawi
Publikationsdatum: 07.10.2021
Verlag: Springer India
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe Sonderheft 3/2022
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI: https://doi.org/10.1007/s12070-021-02913-1

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Association Between Vitamin D Level and PFAPA Syndrome: A Systematic Review

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 3/2022

Fine Governance of Difficult Tracheostomy in Difficult Airway with Stridor and Respiratory Distress

Allergic Fungal Otomastoiditis: A Case Report and Review of Literature

Incorporation of Core Biopsy and FNAB in the Diagnostic Algorithm for Endophytic and Submucosal Laryngeal Malignancies: A Technical Note

Extrapulmonary Tuberculosis: An Otorhinolaryngologist’s Perspective

Intra-ductal Foreign Body (Fish Bone Fragment) as a Cause of Obstructive Sialadenitis: A Case Report

Evaluation of Individual Quality of Life (QOL) Among Patients with Tracheostomy Using WHO-QOL BREF Questionnaire

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO